Email Updates

You are here

AVAC in the News

  • While results for the long-acting HIV prevention medication cabotegravir are promising in men who have sex with men (MSM), there is still no data on this drug in women, begging the question of whether this will be another HIV prevention option that ends up being approved for only one population.

    May 19, 2020
    MedPage Today
  • A major clinical trial comparing ViiV Healthcare’s long-acting injectable cabotegravir dosed every eight weeks with daily oral Truvada (tenofovir disoproxil fumarate/emtricitabine) for use as pre-exposure prophylaxis (PrEP) against HIV halted its blinded, placebo-controlled phase early when cabotegravir was found highly effective at preventing acquisition of the virus among transgender women and cisgender men who have sex with men (MSM).

    May 18, 2020
  • Taken every 2 months, the long-acting injectable drug cabotegravir prevented more HIV infections than daily oral pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC), according to newly announced results from a major Phase 3 study.

    May 18, 2020
    The BodyPro
  • While there is a need for COVID-19 research, it is also important not to erase other important public health issues, such as HIV. Let us not let COVID-19 make us abandon the efforts we have put into HIV research and implementation and stall the progress made this far.

    May 18, 2020
    The Times Malawi
  • Today, we honour HIV Vaccine Awareness Day, as we do every May 18. As an HIV prevention advocate, I want to celebrate and thank the Zambian government for hosting the Imbokodo study, one of only two ongoing HIV vaccine efficacy trials on the globe. As a nation, we should also thank the altruistic women who give their bodies, time and hope as trial participants so that this vaccine study might finally lead us on a path to ending HIV transmission.

    May 18, 2020
    Zambia Daily Mail
  • Experts in infectious disease and public health warn that the COVID-19 pandemic will be with us for a long time unless a vaccine becomes available soon, which is not likely. Estimates of how long it will take for an effective vaccine to come to market range from 12 to 18 months or longer. This situation has given rise to calls for human challenge studies. In these types of studies, researchers inject healthy volunteers with an experimental vaccine, after which the participants are infected with a strain of the disease in order to test the vaccine’s efficacy.

    May 15, 2020
    The Doctor’s Tablet Blog
  • An experimental vaccine seems to give monkeys extended protection from an HIV-like infection -- by "waking up" an arm of the immune system that vaccines normally do not. Experts cautioned that animal research often does not pan out in humans. The decades of work toward an HIV vaccine has been a clear example. But, researchers said, this vaccine works differently, targeting two "arms" of the immune system.

    May 11, 2020
    US News & World Report
  • During the COVID-19 crisis, a number of the ongoing worldwide HIV vaccine and immunotherapy efficacy trials are being paused or curtailed.

    April 22, 2020
  • While the COVID-19 pandemic is raging in the US, Africa faces the prospect of imminent catastrophe, where at least 300,000 Africans could die from the disease and 29 million people may be pushed into extreme poverty. Viruses do not respect borders, and we know that America will not be safe if COVID-19 is out of control on other continents.

    April 21, 2020
    The Hill
  • If one were to list all the titles and positions held by Prof. Helen Rees, who is leading the SA part of a global trial to identify treatments for COVID-19, there would be no space to write anything else.

    April 9, 2020